CoChat
Sign Up
Cited by 21MicroRNA in disease regulationCancer-related molecular mechanisms researchMechanisms of cancer metastasis

miR‑505 inhibits cell growth and EMT by targeting MAP3K3 through the AKT‑NFκB pathway in NSCLC cells

Open access
Tang, Huaping, Lv, Weihong, Sun, Wenxin, Bi, Qiaojie, Hao, Yueqin·2018·International Journal of Molecular Medicine
DOI 10.3892/ijmm.2018.4041PMC PMC6365022
Open this paper in CoChat — free accountOpen PDF

Abstract

MicroRNAs (miRNAs) are short non‑coding RNAs, which generally regulate gene expression at the post‑transcriptional level. Dysregulation of miRNAs has been reported in numerous cancer types, including lung cancer. In the present study, the role of miR‑505 in non‑small cell lung cancer (NSCLC) cells was investigated. miR‑505 served a tumor suppressor role in NSCLC cells. By reverse transcriptase‑quantitative polymerase chain reaction detection, it was demonstrated that miR‑505 was downregulated in NSCLC tissues and cell lines, which is negatively associated with large tumor size, Tumor‑Node‑Metastasis stage and distant metastasis in patients with NSCLC. Functional studies revealed that miR‑505 inhibited cell proliferation, migration, invasion and epithelial‑mesenchymal transition progress in vitro and tumor growth in vivo. Mechanically, mitogen‑activated protein kinase kinase kinase 3 (MAP3K3) was identified as a direct target of miR‑505 by binding to its 3'untranslated region and demonstrated to mediate the tumor suppressor roles of miR‑505 in NSCLC cells. The effect of miR‑505 on the activation of AKT/nuclear factor‑κB (NFκB) pathway, which was downstream targets of MAP3K3, was further analyzed by western blot analysis and immunofluorescence analyses. The data demonstrated the inhibition of the AKT/NFκB pathway upon overexpressing miR‑505 and the activation of AKT/NFκB pathway upon silencing miR‑505. Collectively, the data revealed the novel role and target of miR‑505 in NSCLC cells, which may provide novel insights regarding its role in the carcinogenesis of NSCLC and its potential values for clinical applications.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/ijmm.2018.4041

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • miR-505-3p is known to have a tumor suppressor role.

    “miR-505-3p is one of the miR types known to have a tumor suppressor role (14)(15)(16)(17).”

    From Functional interaction between miR-505-3p and miR-21 contributes to GBM suppression (2026) · cites this paper as [15]

    The Abstract and Discussion state that miR-505 has a tumor-suppressor role in non-small cell lung cancer cells. The paper does not identify the tumor-suppressing form as miR-505-3p; the only exact mention of that form in the retrieved passages is a reference about macrophages. Thus, the tumor-suppressor role is supported, but the claim’s 3p specificity is not established by this copy. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 45

  1. [1]Siegel RL Miller KD Jemal A Cancer statistics, 2018 CA Cancer J Clin 68 7 30 2018 10.3322/caac.21442 29313949 · DOI
  2. [2]Herbst RS Heymach JV Lippman SM Lung cancer N Engl J Med 359 1367 1380 2008 10.1056/NEJMra0802714 18815398 PMC10662965 · DOI
  3. [3]Abbosh C Birkbak NJ Swanton C Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection Nat Rev Clin Oncol 15 577 586 2018 10.1038/s41571-018-0058-3 29968853 · DOI
  4. [4]Frega S Bonanno L Guarneri V Conte P Pasello G Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future? Crit Rev Oncol Hematol 128 19 29 2018 10.1016/j.critrevonc.2018.05.013 29958628 · DOI
  5. [5]Tsiara A Liontos M Kaparelou M Zakopoulou R Bamias A Dimopoulos MA Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) Ann Transl Med 6 144 2018 10.21037/atm.2018.02.07 29862233 PMC5952012 · DOI
  6. [6]Economopoulou P Mountzios G The emerging treatment landscape of advanced non-small cell lung cancer Ann Transl Med 6 138 2018 10.21037/atm.2017.11.07 29862227 PMC5952023 · DOI
  7. [7]Iorio MV Croce CM MicroRNAs in cancer: Small molecules with a huge impact J Clin Oncol 27 5848 5856 2009 10.1200/JCO.2009.24.0317 19884536 PMC2793003 · DOI
  8. [8]Yuan HL Wang T Zhang KH MicroRNAs as potential biomarkers for diagnosis, therapy and prognosis of gastric cancer OncoTargets Ther 11 3891 3900 2018 10.2147/OTT.S156921 PMC6039071 30013369 · DOI
  9. [9]Han Y Li H miRNAs as biomarkers and for the early detection of non-small cell lung cancer (NSCLC) J Thorac Dis 10 3119 3131 2018 10.21037/jtd.2018.05.32 29997981 PMC6006134 · DOI
  10. [11]Calin GA Croce CM MicroRNA-cancer connection: The beginning of a new tale Cancer Res 66 7390 7394 2006 10.1158/0008-5472.CAN-06-0800 16885332 · DOI
  11. [12]Calin GA Croce CM MicroRNA signatures in human cancers Nat Rev Cancer 6 857 866 2006 10.1038/nrc1997 17060945 · DOI
  12. [13]Zhang B Pan X Cobb GP Anderson TA microRNAs as oncogenes and tumor suppressors Dev Biol 302 1 12 2007 10.1016/j.ydbio.2006.08.028 16989803 · DOI
  13. [14]Farazi TA Hoell JI Morozov P Tuschl T MicroRNAs in human cancer Adv Exp Med Biol 774 1 20 2013 10.1007/978-94-007-5590-1_1 23377965 PMC3704221 · DOI
  14. [15]Tang W Wan S Yang Z Teschendorff AE Zou Q Tumor origin detection with tissue-specific miRNA and DNA methylation markers Bioinformatics 34 398 406 2018 10.1093/bioinformatics/btx622 29028927 · DOI
  15. [16]Yamamoto Y Yoshioka Y Minoura K Takahashi RU Takeshita F Taya T Horii R Fukuoka Y Kato T Kosaka N An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells Mol Cancer 10 135 2011 10.1186/1476-4598-10-135 22051041 PMC3247093 · DOI
  16. [17]Yang Q Jia C Wang P Xiong M Cui J Li L Wang W Wu Q Chen Y Zhang T MicroRNA-505 identified from patients with essential hypertension impairs endothelial cell migration and tube formation Int J Cardiol 177 925 934 2014 10.1016/j.ijcard.2014.09.204 25449503 · DOI
  17. [18]Escate R Mata P Cepeda JM Padró T Badimon L miR-505-3p controls chemokine receptor up-regulation in macrophages: Role in familial hypercholesterolemia FASEB J 32 601 612 2018 10.1096/fj.201700476RR 29457550 · DOI
  18. [19]Liu YJ Li W Chang F Liu JN Lin JX Chen DX MicroRNA-505 is downregulated in human osteosarcoma and regulates cell proliferation, migration and invasion Oncol Rep 39 491 500 2018 29251324 PMC5783616
  19. [20]Lu L Qiu C Li D Bai G Liang J Yang Q MicroRNA-505 suppresses proliferation and invasion in hepatoma cells by directly targeting high-mobility group box 1 Life Sci 157 12 18 2016 10.1016/j.lfs.2016.05.039 27259809 · DOI
  20. [21]Ma C Xu B Husaiyin S Wang L Wusainahong K Ma J Zhu K Niyazi M MicroRNA-505 predicts prognosis and acts as tumor inhibitor in cervical carcinoma with inverse association with FZD4 Biomed Pharmacother 92 586 594 2017 10.1016/j.biopha.2017.04.028 28577497 · DOI
  21. [22]Chen S Sun KX Liu BL Zong ZH Zhao Y MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-α Mol Cancer 15 11 2016 10.1186/s12943-016-0496-4 26832151 PMC4736705 · DOI · Paper page
  22. [23]Paner GP Stadler WM Hansel DE Montironi R Lin DW Amin MB Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers Eur Urol 73 560 569 2018 10.1016/j.eururo.2017.12.018 29325693 · DOI
  23. [24]Livak KJ Schmittgen TD Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method Methods 25 402 408 2001 10.1006/meth.2001.1262 11846609 · DOI · Paper page
  24. [25]Yang Z Wang XL Bai R Liu WY Li X Liu M Tang H miR-23a promotes IKKα expression but suppresses ST7L expression to contribute to the malignancy of epithelial ovarian cancer cells Br J Cancer 115 731 740 2016 10.1038/bjc.2016.244 27537390 PMC5023779 · DOI
  25. [26]Samanta AK Huang HJ Le XF Mao W Lu KH Bast RC Jr Liao WS MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma Cancer 115 3897 3908 2009 10.1002/cncr.24445 19517469 PMC3061353 · DOI
  26. [27]Landi MT Zhao Y Rotunno M Koshiol J Liu H Bergen AW Rubagotti M Goldstein AM Linnoila I Marincola FM MicroRNA expression differentiates histology and predicts survival of lung cancer Clin Cancer Res 16 430 441 2010 10.1158/1078-0432.CCR-09-1736 20068076 PMC3163170 · DOI
  27. [28]Du X Zhang J Wang J Lin X Ding F Role of miRNA in lung cancer-potential biomarkers and therapies Curr Pharm Des 23 5997 6010 2018 10.2174/1381612823666170714150118 28714414 · DOI
  28. [29]Yang CL Zheng XL Ye K Ge H Sun YN Lu YF Fan QX MicroRNA-183 acts as a tumor suppressor in human non-small cell lung cancer by down-regulating MTA1. Cell Physiol Biochem 46 93 106 2018 29587281
  29. [30]Qi Z Zhang B Zhang J Hu Q Xu F Chen B Zhu C MicroRNA-30b inhibits non-small cell lung cancer cell growth by targeting the epidermal growth factor receptor Neoplasma 65 192 200 2018 10.4149/neo_2018_170217N118 29534579 · DOI
  30. [31]Huang RS Zheng YL Li C Ding C Xu C Zhao J MicroRNA-485-5p suppresses growth and metastasis in non-small cell lung cancer cells by targeting IGF2BP2 Life Sci 199 104 111 2018 10.1016/j.lfs.2018.03.005 29510198 · DOI · Paper page
  31. [32]Wu D Liu J Chen J He H Ma H Lv X MiR-449a suppresses tumor growth, migration and invasion in non-small cell lung cancer by targeting HMGB1-mediated NF-κB signaling way Oncol Res 3 21 2018 Epub ahead of print PMC7848403 29562957
  32. [33]Liu M Zhang Y Zhang J Cai H Zhang C Yang Z Niu Y Wang H Wei X Wang W MicroRNA-1253 suppresses cell proliferation and invasion of non-small-cell lung carcinoma by targeting WNT5A Cell Death Dis 9 189 2018 10.1038/s41419-017-0218-x 29415994 PMC5833797 · DOI
  33. [34]Liu J Jia Y Jia L Li T Yang L Zhang G MicroRNA-615-3p inhibits the tumor growth and metastasis of NSCLC via inhibiting IGF2 Oncol Res 3 21 2018 Epub ahead of print PMC7848428 29562959
  34. [35]Ding X Zhong T Jiang L Huang J Xia Y Hu R miR-25 enhances cell migration and invasion in non-small-cell lung cancer cells via ERK signaling pathway by inhibiting KLF4 Mol Med Rep 17 7005 7016 2018 29568911 PMC5928655
  35. [36]Chang L Karin M Mammalian MAP kinase signalling cascades Nature 410 37 40 2001 10.1038/35065000 11242034 · DOI
  36. [37]Johnson GL Lapadat R Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases Science 298 1911 1912 2002 10.1126/science.1072682 12471242 · DOI · Paper page
  37. [38]Yang J Lin Y Guo Z Cheng J Huang J Deng L Liao W Chen Z Liu Z Su B The essential role of MEKK3 in TNF-induced NF-kappaB activation Nat Immunol 2 620 624 2001 10.1038/89769 11429546 · DOI
  38. [39]Hasan R Sharma R Saraya A Chattopadhyay TK DattaGupta S Walfish PG Chauhan SS Ralhan R Mitogen activated protein kinase kinase kinase 3 (MAP3K3/MEKK3) overexpression is an early event in esophageal tumorigenesis and is a predictor of poor disease prognosis BMC Cancer 14 1 7 2014 10.1186/1471-2407-14-2 24383423 PMC3890584 · DOI
  39. [40]Fan Y Ge N Wang X Sun W Mao R Bu W Creighton CJ Zheng P Vasudevan S An L Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells J Pathol 232 75 86 2014 10.1002/path.4283 24122835 PMC3966110 · DOI
  40. [41]Jia W Dong Y Tao L Pang L Ren Y Liang W Jiang J Cheng G Zhang WJ Yuan X MAP3K3 overexpression is associated with poor survival in ovarian carcinoma Hum Pathol 50 162 169 2016 10.1016/j.humpath.2015.12.011 26997451 · DOI
  41. [42]He Y Wang L Liu W Zhong J Bai S Wang Z Thomas DG Lin J Reddy RM Ramnath N MAP3K3 expression in tumor cells and tumor-infiltrating lymphocytes is correlated with favorable patient survival in lung cancer Sci Rep 5 11471 2015 10.1038/srep11471 26088427 PMC4650617 · DOI
  42. [43]Iqbal MA Arora S Prakasam G Calin GA Syed MA MicroRNA in lung cancer: Role, mechanisms, pathways and therapeutic relevance Mol Aspects Med 18 30065 30067 2018 30102929
  43. [44]Yao L Ye Y Mao H Lu F He X Lu G Zhang S MicroRNA-124 regulates the expression of MEKK3 in the inflammatory pathogenesis of Parkinson's disease J Neuroinflammation 15 13 2018 10.1186/s12974-018-1053-4 29329581 PMC5767033 · DOI
  44. [45]Zheng Y Liu H Kong Y miR-188 promotes senescence of lineage-negative bone marrow cells by targeting MAP3K3 expression FEBS Lett 591 2290 2298 2017 10.1002/1873-3468.12720 28640956 · DOI
  45. [46]Zhao L Ni X Zhao L Zhang Y Jin D Yin W Wang D Zhang W MiroRNA-188 acts as tumor suppressor in non-small-cell lung cancer by targeting MAP3K3 Mol Pharm 15 1682 1689 2018 10.1021/acs.molpharmaceut.8b00071 29528232 · DOI

Cited by

Sorted by citations

Authors
Tang, H., Lv, W., Sun, W., Bi, Q., & Hao, Y.
Affiliations
Qingdao Municipal Hospital (CN)
Corresponding author
Hao, Yueqin
ORCID
Venue
International Journal of Molecular Medicine
Publisher
Spandidos Publications
Published
2018-12-31
Volume
43
Issue
3
Pages
1203-1216
ISSN
  • 1107-3756 (ISSN-L)
  • 1791-244X
DOI
10.3892/ijmm.2018.4041
PMC
PMC6365022
OpenAlex
W2907986716
Cited by
21
References
1
Citations by year
2026: 1 · 2025: 1 · 2024: 3 · 2023: 3 · 2022: 2 · 2021: 3 · 2020: 4 · 2019: 4
FWCI
0.82
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • International Journal of Molecular Medicine (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
Keywords
miR-505, non-small cell lung cancer, MAP3K3, epithelial-mesenchymal transition, tumor suppressor microRNA, cell proliferation, cell migration and invasion, metastasis
MeSH terms
Adult, Aged, Animals, Carcinoma, Non-Small-Cell Lung, Cell Cycle, Cell Movement, Female, Humans, Lung Neoplasms, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Tumor Stem Cell Assay, Signal Transduction, Gene Expression Regulation, Neoplastic, NF-kappa B, Genes, Reporter, RNA Interference, MicroRNAs, Cell Line, Tumor, MAP Kinase Kinase Kinase 3, Cell Proliferation, Proto-Oncogene Proteins c-akt, Mice, Epithelial-Mesenchymal Transition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review